Enhancing the Solubility and Dissolution Performance of Safinamide Using Salts

Safinamide (SAF) is an anti-Parkinson’s disease (PD) drug that has selective monoamine oxidase type-B (MAO-B) inhibition activity. In 2017, SAF was approved by the U.S. Food and Drug Administration (FDA) as safinamide mesylate (SAF-MS, marketed as Xadago). Owing to its poor solubility in water, SAF...

詳細記述

書誌詳細

出版年:	Crystals
主要な著者:	Lei Gao, Qian Liu, Xian-Rui Zhang
フォーマット:	論文
言語:	英語
出版事項:	MDPI AG 2020-10-01
主題:	safinamide salts X-ray diffraction solubility dissolution rate
オンライン･アクセス:	https://www.mdpi.com/2073-4352/10/11/989